Janessa M. Smith, PharmD, BCPS, Paul A. Pham, Pharm.D.



  • Malaria (acute) in combination with sulfadoxine and quinine in the treatment of chloroquine-resistant Plasmodium falciparum malaria.
    • Resistance prevalent worldwide; not recommended as a prophylactic agent for travelers to most areas (not available in US).
  • Toxoplasmosis (in combination with sulfadiazine OR clindamycin plus leucovorin).

Non-FDA approved uses

  • Isospora

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: October 28, 2017